Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2015-16 | Page 35

### Independent Auditors' Report
To The Shareholders of
Beximco Pharmaceuticals Limited

#### Report on the Financial Statements
We have audited the accompanying financial statements of Beximco Pharmaceuticals Limited, which comprises the Statement of Financial Position as at 30 June 2016, the Statement of Profit or Loss and other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the period from 01 January 2015 to 30 June 2016 (18 months) then ended and a summary of significant accounting policies and other relevant explanatory notes.

#### Management's Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards (IFRSs), Bangladesh Financial Reporting Standards (BFRSs), and Bangladesh Accounting Standards (BASs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

#### Auditors' Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA) and Bangladesh Standards on Auditing (BSA). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstance, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion
In our opinion, the financial statements give a true and fair view of the financial position of the Company as at 30 June 2016, and of its financial performance and its cash flows for the period of 18 months then ended in accordance with International Financial Reporting Standards (IFRSs) and Bangladesh Financial Reporting Standards (BFRSs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

#### Other matter
Financial Statements of the Company for the year ended 31 December 2015 and period ended 30 June 2016 have separately been audited by us. Now the Company is required to follow accounting year as July to June as per Finance Act 2015. For this purpose, separately audited financial statements have been compiled as per directives of The Bangladesh Securities and Exchange Commission (BSEC).

#### Report on Other Legal and Regulatory Requirements
In accordance with the requirements of the Companies Act 1994 and the Securities and Exchange Rules 1987, we report that:

(a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
(b) in our opinion, proper books of account as required by law have been kept by the company so far as it appeared from our examination of these books;
(c) the Statement of Financial Position (Balance Sheet) and Statement of Profit or Loss and other Comprehensive Income (Profit and Loss Account) dealt with by the report are in agreement with the books of account; and
(d) the expenditure incurred was for the purposes of the company's business.

Beximco Pharmaceuticals Limited
Statement of Financial Position
As at June 30, 2016

Amount in Taka

| Particulars | Notes | June 30, 2016 | December 31, 2014 |
|---|---|---|---|
| **ASSETS** | | | |
| **Non-Current Assets** | | **22,620,900,165** | **20,634,246,854** |
| Property, Plant and Equipment- Carrying Value 4 (a) |  | 22,235,892,802 | 20,393,278,737 |
| Intangible Assets | 3.3 & 5 | 380,260,529 | 235,208,190 |
| Investment in Shares 6 (a) |  | 4,746,834 | 5,759,927 |
| | | | |
| **Current Assets** | | **8,528,007,810** | **8,366,279,107** |
| Inventories | 7 | 2,770,331,675 | 2,493,657,338 |
| Spares & Supplies | 8 | 614,606,112 | 554,183,898 |
| Accounts Receivable | 9 | 1,680,606,796 | 1,397,498,648 |
| Loans, Advances and Deposits | 10 | 1,802,304,185 | 1,223,673,153 |
| Short Term Investment | 11 | 1,439,037,813 | 2,475,026,831 |
| Cash and Cash Equivalents | 12 | 221,121,229 | 222,239,239 |
| | | | |
| **TOTAL ASSETS** | | **31,148,907,975** | **29,000,525,961** |
| | | | |
| **EQUITY AND LIABILITIES** | | | |
| **Shareholders' Equity** | | **23,059,412,409** | **20,920,185,325** |
| Issued Share Capital | 13 | 3,862,442,340 | 3,678,516,520 |
| Share Premium | | 5,269,474,690 | 5,269,474,690 |
| Excess of Issue Price over Face Value of GDRs | 14 | 1,689,636,958 | 1,689,636,958 |
| Capital Reserve on Merger | | 294,950,950 | 294,950,950 |
| Revaluation Surplus 4(b) |  | 1,225,100,042 | 1,299,220,315 |
| Fair Value Gain on Investment | | 1,295,558 | 2,308,651 |
| Retained Earnings | | 10,716,511,871 | 8,686,077,241 |
| | | | |
| **Non-Current Liabilities** | | **5,106,928,058** | **3,372,593,206** |
| Long Term Borrowings-Net off Current Maturity (Secured) | 15 | 2,366,006,599 | 901,709,327 |
| Liability for Gratuity and WPPF & Welfare Funds | 16 | 984,198,459 | 741,522,518 |
| Deferred Tax Liability | 17 | 1,756,723,000 | 1,729,361,361 |
| | | | |
| **Current Liabilities and Provisions** | | **2,982,567,508** | **4,707,747,430** |
| Short Term Borrowings (Secured) 18 (a) |  | 1,109,644,270 | 3,153,121,293 |
| Long Term Borrowings-Current Maturity (Secured) | 19 | 920,388,531 | 663,838,072 |
| Creditors and Other Payables | 20 | 453,828,612 | 357,710,839 |
| Accrued Expenses | 21 | 151,086,775 | 164,283,115 |
| Dividend Payable | | 385,507 | 454,720 |
| Income Tax Payable | 22 | 347,233,813 | 368,339,391 |
| | | | |
| **TOTAL EQUITY AND LIABILITIES** | | **31,148,907,975** | **29,000,525,961** |